TABLE 2.
Baseline characteristics.
| Characteristic | Overall population | AChR‐Ab+ participants | AChR‐Ab− participants | |||
|---|---|---|---|---|---|---|
| Efgartigimod (n = 84) | Placebo (n = 83) | Efgartigimod (n = 65) | Placebo (n = 64) | Efgartigimod (n = 19) | Placebo (n = 19) | |
| Age, mean (SD), years | 45.9 (14.4) | 48.2 (15.0) | 44.7 (15.0) | 49.2 (15.5) | 50.2 (11.6) | 44.8 (12.6) |
| Sex, female, n (%) | 63 (75) | 55 (66) | 46 (71) | 40 (63) | 17 (90) | 15 (79) |
| Time since diagnosis, mean (SD), years | 10.1 (9.0) | 8.8 (7.6) | 9.7 (8.3) | 8.9 (8.2) | 11.7 (11.5) | 8.5 (5.2) |
| Total MG‐ADL score, mean (SD) | 9.2 (2.6) | 8.8 (2.3) | 9.0 (2.5) | 8.6 (2.1) | 9.7 (3.1) | 9.8 (2.5) |
| Total QMG score, mean (SD) | 16.2 (5.0) | 15.5 (4.6) | 16.0 (5.1) | 15.2 (4.4) | 16.6 (4.6) | 16.5 (5.2) |
| MGFA class at screening, n (%) | ||||||
| Class II | 34 (40) | 31 (37) | 28 (43) | 25 (39) | 6 (32) | 6 (32) |
| Class III | 47 (56) | 49 (59) | 35 (54) | 36 (56) | 12 (63) | 13 (68) |
| Class IV | 3 (4) | 3 (4) | 2 (3) | 3 (5) | 1 (5) | 0 (0) |
| Prior treatment with NSIST, n (%) | 62 (74) | 57 (69) | 47 (72) | 43 (67) | 15 (79) | 14 (74) |
| MG therapies at baseline, n (%) | ||||||
| Any AChEI | 71 (85) | 67 (81) | 57 (88) | 57 (89) | 14 (74) | 10 (53) |
| Any steroid | 60 (71) | 67 (81) | 46 (71) | 51 (80) | 14 (74) | 16 (84) |
| Any NSIST | 51 (61) | 51 (61) | 40 (62) | 37 (58) | 11 (58) | 14 (74) |
| Steroid and NSIST | 43 (51) | 44 (53) | 34 (52) | 31 (48) | 9 (47) | 13 (68) |
|
No steroid or NSIST (AChEI only) |
16 (19) | 7 (8) | 13 (20) | 6 (9) | 3 (16) | 1 (5) |
Abbreviations: AChEI, acetylcholinesterase inhibitor; AChR‐Ab, anti‐acetylcholine receptor antibody; MG, myasthenia gravis; MG‐ADL, Myasthenia Gravis Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; NSIST, nonsteroidal immunosuppressive therapy; QMG, Quantitative Myasthenia Gravis.